Serving hundreds of leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Accenture
Citi
Cipla
Julphar
AstraZeneca
Mallinckrodt
Fish and Richardson

Pharmaceutical companies with the most orphan drugs

Orphan drug exclusivity is granted to drugs addressing rare 'orphan diseases' — those affecting fewer than 200,000 Americans.

The protection granted to orphan drugs is quite strong. The FDA is barred from approving any other biologic or small-molecule drug, generic/follow-on or otherwise, treating the same orphan disease for seven years.

This chart shows the companies which have received the most orphan drug exclusivities in the past five years.

The companies with the most orphan drug approvals are:

Back to Pharmaceutical Industry Infographics

For more information try a trial or see the plans and pricing